2666-3643

JTO Clinical and Research Reports

Elsevier

View prefix report (10.1016)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 867 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact867 DOIs
2

Attach ORCID iDs across 503 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact503 DOIs
3

Deposit reference lists for 61 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact61 DOIs

DOIs for this ISSN

Showing the top 5 of 867 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 20… (10.1016/j.jtocrr.2020.100015)
Abstract ORCID
87.41 55
2 The Role of Interleukin 1β in the Pathogenesis of Lung Cance… (10.1016/j.jtocrr.2020.100001)
Abstract ORCID
79.55 38
3 Outcomes With Pembrolizumab Monotherapy in Patients With Pro… (10.1016/j.jtocrr.2021.100205)
Abstract ORCID
78.99 37
4 Desensitizing Effect of Cancer Cachexia on Immune Checkpoint… (10.1016/j.jtocrr.2020.100020)
Abstract ORCID
74.57 30
5 Implementing Lung Cancer Screening in Europe: Taking a Syste… (10.1016/j.jtocrr.2022.100329)
Abstract ORCID
73.86 29
6 Pembrolizumab Plus Chemotherapy for Chinese Patients With Me… (10.1016/j.jtocrr.2021.100225)
Abstract ORCID
70.75 25
7 Severe Radiation-Induced Lymphopenia Attenuates the Benefit… (10.1016/j.jtocrr.2022.100391)
Abstract ORCID
69.01 23
8 Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC:… (10.1016/j.jtocrr.2020.100108)
Abstract ORCID
67.12 21
9 EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation… (10.1016/j.jtocrr.2020.100051)
Abstract ORCID
66.11 20
10 Real-World Response and Outcomes in Patients With NSCLC With… (10.1016/j.jtocrr.2023.100558)
Abstract ORCID
66.11 20
11 Ultrarapid EGFR Mutation Screening Followed by Comprehensive… (10.1016/j.jtocrr.2020.100077)
Abstract ORCID
65.05 19
12 A Real-World Evaluation of Atezolizumab Plus Platinum-Etopos… (10.1016/j.jtocrr.2021.100249)
Abstract ORCID
65.05 19
13 Impact of Performance Status on Survival Outcomes and Health… (10.1016/j.jtocrr.2023.100482)
Abstract ORCID
65.05 19
14 A Real-World Study on the Effectiveness and Safety of Pembro… (10.1016/j.jtocrr.2021.100265)
Abstract ORCID
62.76 17
15 Impact of Brain Metastases on Treatment Patterns and Outcome… (10.1016/j.jtocrr.2022.100330)
Abstract ORCID
62.76 17
16 Biomarker Testing for Patients With Advanced/Metastatic Nons… (10.1016/j.jtocrr.2022.100336)
Abstract ORCID
62.76 17
17 Retrospective Evaluation of the Use of Pembrolizumab in Mali… (10.1016/j.jtocrr.2020.100075)
Abstract ORCID
60.21 15
18 Response to Immune Checkpoint Inhibition as Monotherapy or i… (10.1016/j.jtocrr.2021.100187)
Abstract ORCID
60.21 15
19 Phase 2 Study of Olaparib in Malignant Mesothelioma and Corr… (10.1016/j.jtocrr.2021.100231)
Abstract ORCID
60.21 15
20 The Genomics of Young Lung Cancer: Comprehensive Tissue Geno… (10.1016/j.jtocrr.2021.100194)
Abstract ORCID
58.80 14
21 Association Between Immune-Related Adverse Events and Clinic… (10.1016/j.jtocrr.2020.100074)
Abstract ORCID
57.31 13
22 Efficacy of Targeted Inhibitors in Metastatic Lung Squamous… (10.1016/j.jtocrr.2021.100237)
Abstract ORCID
57.31 13
23 Clinical Characteristics and Outcomes in Advanced KRAS-Mutat… (10.1016/j.jtocrr.2021.100261)
Abstract ORCID
57.31 13
24 Prognostic Value of Clinical Staging According to TNM in Pat… (10.1016/j.jtocrr.2021.100266)
Abstract ORCID
57.31 13
25 Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechal… (10.1016/j.jtocrr.2022.100309)
Abstract ORCID
57.31 13
26 A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa… (10.1016/j.jtocrr.2020.100048)
Abstract ORCID
55.70 12
27 Japanese Lung Cancer Society Guidelines for Stage IV NSCLC W… (10.1016/j.jtocrr.2020.100107)
Abstract ORCID
55.70 12
28 Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mu… (10.1016/j.jtocrr.2021.100213)
Abstract ORCID
55.70 12
29 Lung Cancer Screening Knowledge and Perceived Barriers Among… (10.1016/j.jtocrr.2022.100331)
Abstract ORCID
55.70 12
30 Automating Access to Real-World Evidence (10.1016/j.jtocrr.2022.100340)
Abstract ORCID
55.70 12
31 Medicolegal Considerations in Multidisciplinary Cancer Care (10.1016/j.jtocrr.2020.100073)
Abstract ORCID
53.96 11
32 Retrospective Real-World Outcomes for Patients With ALK-Rear… (10.1016/j.jtocrr.2021.100157)
Abstract ORCID
53.96 11
33 A Real-World Analysis of the Use of Systemic Therapy in Mali… (10.1016/j.jtocrr.2022.100280)
Abstract ORCID
53.96 11
34 Assessing Pathologic Response in Resected Lung Cancers: Curr… (10.1016/j.jtocrr.2022.100310)
Abstract ORCID
53.96 11
35 Overview of Drug-Drug Interactions Between Ritonavir-Boosted… (10.1016/j.jtocrr.2022.100452)
Abstract ORCID
53.96 11
36 Osimertinib in NSCLC With Atypical EGFR-Activating Mutations… (10.1016/j.jtocrr.2022.100459)
Abstract ORCID
53.96 11
37 Blood-Based Surveillance Monitoring of Circulating Tumor DNA… (10.1016/j.jtocrr.2020.100024)
Abstract ORCID
52.07 10
38 RET Fusion: Joining the Ranks of Targetable Molecular Driver… (10.1016/j.jtocrr.2020.100050)
Abstract ORCID
52.07 10
39 Circulating Tumor DNA as a Biomarker of Radiographic Tumor B… (10.1016/j.jtocrr.2020.100110)
Abstract ORCID
52.07 10
40 A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206… (10.1016/j.jtocrr.2020.100116)
Abstract ORCID
52.07 10
41 Brief Report: Risk Prediction Model Versus United States Pre… (10.1016/j.jtocrr.2020.100137)
Abstract ORCID
52.07 10
42 A Phase 1b Study of Telisotuzumab Vedotin in Combination Wit… (10.1016/j.jtocrr.2021.100262)
Abstract ORCID
52.07 10
43 Functional Trajectories and Resilience Among Adults With Adv… (10.1016/j.jtocrr.2022.100334)
Abstract ORCID
52.07 10
44 Frailty Is Associated With Adverse Postoperative Outcomes Af… (10.1016/j.jtocrr.2022.100414)
Abstract ORCID
52.07 10
45 First-Line Pembrolizumab Plus Chemotherapy for Advanced Squa… (10.1016/j.jtocrr.2022.100444)
Abstract ORCID
52.07 10
46 Acquired Resistance to Osimertinib Plus Savolitinib Is Media… (10.1016/j.jtocrr.2020.100071)
Abstract ORCID
50.00 9
47 A Systematic Review and Meta-Analysis of Clinical Characteri… (10.1016/j.jtocrr.2020.100141)
Abstract ORCID
50.00 9
48 Important Surgical and Clinical End Points in Neoadjuvant Im… (10.1016/j.jtocrr.2021.100221)
Abstract ORCID
50.00 9
49 Cardiac Safety Assessment of Lazertinib: Findings From Patie… (10.1016/j.jtocrr.2021.100224)
Abstract ORCID
50.00 9
50 Concurrent Chemoradiation With or Without Durvalumab in Elde… (10.1016/j.jtocrr.2021.100251)
Abstract ORCID
50.00 9